All practice questions

4736 questions

All types4,736 Multiple choice2,413 Multiple select567 Numeric127 Matching858 Ordering771

A $28$ -year-old man is brought to the emergency department by paramedics after being found unresponsive at home. His respiratory rate is $6$ breaths/min, and oxygen saturation is $84\%$ on room air. Physical examination reveals pinpoint pupils and cyanosis of the lips. Paramedics administered a standard $0.4$ mg intravenous dose of naloxone en route with no clinical improvement. In the emergency department, the patient requires three additional $2.0$ mg intravenous doses of naloxone before his respiratory rate improves to $14$ breaths/min and he regains consciousness. Review of his electronic medical record reveals that he recently enrolled in an outpatient medication-assisted treatment program for substance use disorder. Which of the following pharmacodynamic characteristics of this patient's most likely maintenance medication best explains the need for unusually high doses of the reversal agent?

High receptor binding affinity with slow dissociation kinetics

Irreversible covalent binding to the target mu-opioid receptors

Extensive distribution into adipose tissue with a prolonged elimination half-life

Induction of hepatic cytochrome P450 enzymes leading to rapid antidote clearance

Agonist-induced downregulation of mu-opioid receptors requiring higher antidote concentrations

Show answer & explanation

Answer: High receptor binding affinity with slow dissociation kinetics

Answer

High receptor binding affinity with slow dissociation kinetics

The correct answer is high receptor binding affinity with slow dissociation kinetics. The patient's presentation of an opioid toxidrome despite enrollment in a substance use treatment program strongly suggests toxicity from buprenorphine, a partial mu-opioid agonist used for medication-assisted treatment. Buprenorphine is unique among opioids due to its exceptionally high binding affinity for the mu-opioid receptor—affinity that exceeds even that of the competitive antagonist naloxone. Additionally, it has very slow receptor dissociation kinetics. Because buprenorphine binds tightly and releases slowly, standard doses of naloxone (e.g.,

0.4

mg) are often insufficient to competitively displace it from the receptors. Consequently, clinicians must administer significantly higher or repeated doses of naloxone (often up to

10

mg) to successfully reverse buprenorphine-induced respiratory depression.

Step-by-Step Solution

Identify the primary clinical toxidrome and contextual clues.

The patient presents with the classic opioid overdose triad (respiratory depression, pinpoint pupils, CNS depression) and is enrolled in an outpatient treatment program, highly suggesting buprenorphine toxicity.

Recognizing the likely offending agent is required to analyze its specific pharmacological properties.

Analyze the atypical response to the standard intervention.

The patient failed to respond to a standard

0.4

mg dose of naloxone and required massive doses (total

6.4

mg) to achieve respiratory reversal.

This clinical resistance indicates that the offending opioid is exceptionally difficult to displace from the receptor.

Correlate the clinical resistance with pharmacodynamic principles.

Buprenorphine has a greater binding affinity for the mu-opioid receptor than naloxone and exhibits slow dissociation kinetics, necessitating much higher concentrations of a competitive antagonist to achieve displacement.

Understanding the difference between pharmacokinetic distribution and pharmacodynamic receptor affinity is essential for selecting the correct mechanism.

Key Concept

Pharmacodynamics of partial agonists and competitive antagonism (Buprenorphine vs. Naloxone).

Estimated Time:2m 0s

Question 82Question →

A 55-year-old female patient is hospitalized for the management of severe pneumonia complicated by sepsis. Her current body weight is $80 \text{ kg}$ . The medical team decides to initiate therapy with an intravenous antimicrobial agent. This medication has a volume of distribution ( $V_d$ ) of $0.5 \text{ L/kg}$ and follows first-order elimination kinetics with a half-life ( $t_{1/2}$ ) of $6.93 \text{ hours}$ . The drug is prescribed to be administered intermittently as an intravenous infusion every $12 \text{ hours}$ . To achieve optimal bactericidal activity, the target average steady-state plasma concentration ( $C_{ss,avg}$ ) is $10 \text{ mg/L}$ . Assuming $100\%$ bioavailability for the intravenous route, what maintenance dose should be administered every $12 \text{ hours}$ ?

Show answer & explanation

Answer: 480

Answer

480

The maintenance dose (

MD

) is the amount of drug required to replace what is eliminated over a dosing interval (

\tau

) to maintain a target average steady-state concentration (

C_{ss,avg}

). The formula is

MD = \frac{C_{ss,avg} \times CL \times \tau}{F}

. First, clearance (

CL

) must be determined. Clearance is the product of the elimination rate constant (

k_e

) and the volume of distribution (

V_d

). The patient's total

V_d

0.5 \text{ L/kg} \times 80 \text{ kg} = 40 \text{ L}

. The elimination rate constant is

k_e = \frac{0.693}{t_{1/2}} = \frac{0.693}{6.93 \text{ hours}} = 0.1 \text{ hr}^{-1}

. Therefore,

CL = 0.1 \text{ hr}^{-1} \times 40 \text{ L} = 4 \text{ L/hr}

. For an intravenous drug (

F = 1

), the maintenance dose administered every

12 \text{ hours}

MD = 10 \text{ mg/L} \times 4 \text{ L/hr} \times 12 \text{ hours} = 480 \text{ mg}

Step-by-Step Solution

Calculate the patient's total volume of distribution (

V_d

V_d = 0.5 \text{ L/kg} \times 80 \text{ kg} = 40 \text{ L}

Total volume of distribution is required to calculate the total body clearance of the drug.

Calculate the elimination rate constant (

k_e

) and total body clearance (

CL

k_e = \frac{0.693}{6.93 \text{ hr}} = 0.1 \text{ hr}^{-1}

. Clearance (

CL

) =

k_e \times V_d = 0.1 \text{ hr}^{-1} \times 40 \text{ L} = 4 \text{ L/hr}

Clearance determines the rate at which the drug must be replaced to maintain steady-state concentrations.

Calculate the maintenance dose (

MD

) for the specified dosing interval.

MD = C_{ss,avg} \times CL \times \tau = 10 \text{ mg/L} \times 4 \text{ L/hr} \times 12 \text{ hr} = 480 \text{ mg}

The maintenance dose replaces the amount of drug cleared over one dosing interval (

\tau

) to maintain the target steady-state concentration.

Key Concept

Calculation of maintenance dose requires determining clearance from half-life and volume of distribution, then multiplying by the target steady-state concentration and dosing interval.

Question 83Question →

An ambulatory care pharmacist reviews the medication profile of a 62-year-old woman with a mechanical aortic valve. She is currently taking a stable dose of warfarin, and her international normalized ratio (INR) has been consistently in the therapeutic range of 2.5 to 3.5. The patient was recently diagnosed with vaginal candidiasis and was prescribed a short course of oral fluconazole by her primary care provider. Four days later, she presents to the urgent care clinic complaining of significant gingival bleeding and large ecchymoses on her extremities. Laboratory testing reveals an INR of 7.2. Which of the following pharmacokinetic mechanisms is the most likely cause of this patient's elevated INR and subsequent bleeding?

Inhibition of cytochrome P450-mediated metabolism

Displacement of the anticoagulant from plasma albumin

Induction of hepatic cytochrome P450 enzymes

Decreased renal clearance of active drug metabolites

Eradication of intestinal flora leading to decreased vitamin K synthesis

Show answer & explanation

Answer: Inhibition of cytochrome P450-mediated metabolism

Answer

Inhibition of cytochrome P450-mediated metabolism

The correct answer correctly identifies that fluconazole causes a classic pharmacokinetic drug-drug interaction through the inhibition of cytochrome P450 enzymes. Specifically, it inhibits CYP2C9, the primary metabolic pathway for the highly active S-enantiomer of warfarin. This inhibition abruptly halts the hepatic clearance of warfarin, causing plasma levels to rise rapidly and extending the anticoagulant effect, which manifests as an unexpectedly high INR and spontaneous bleeding.

Step-by-Step Solution

Identify the patient's core clinical problem.

A patient stabilized on warfarin developed a supratherapeutic INR (7.2) and bleeding shortly after starting fluconazole.

Establishing the sequence of events is necessary to identify the drug-drug interaction.

Determine the pharmacokinetic properties of the newly added drug (fluconazole).

Fluconazole is a well-known, potent inhibitor of the hepatic cytochrome P450 enzyme CYP2C9.

Knowing the metabolic profile of the interacting drug reveals the mechanism of the interaction.

Correlate the mechanism with the clinical outcome.

Warfarin's highly active S-enantiomer is metabolized by CYP2C9. Inhibition of this enzyme decreases warfarin clearance, leading to accumulation and an elevated INR.

Linking the enzyme inhibition to the decreased clearance of warfarin confirms the correct mechanism of toxicity.

Key Concept

Fluconazole strongly inhibits CYP2C9, which is the primary enzyme responsible for metabolizing the more potent S-enantiomer of warfarin, leading to decreased clearance, drug accumulation, and an increased risk of bleeding.

Question 84Question →

A $31$ -year-old woman, G1P0, at $33$ weeks gestation presents to the emergency department with severe right upper quadrant abdominal pain and nausea for the past $6$ hours. Her blood pressure is $168/110\text{ mm Hg}$ , and pulse is $98/\text{min}$ . Physical examination reveals marked tenderness over the liver. Fetal heart rate monitoring is reassuring.

Laboratory studies show:
- Hemoglobin: $8.8\text{ g/dL}$
- Platelets: $55,000/\text{mm}^3$
- Aspartate aminotransferase (AST): $480\text{ U/L}$
- Alanine aminotransferase (ALT): $510\text{ U/L}$
- Lactate dehydrogenase (LDH): $950\text{ U/L}$
- Total bilirubin: $2.2\text{ mg/dL}$
- Prothrombin time (PT): $11.5\text{ seconds}$ (Normal: $11-14\text{ seconds}$ )
- Partial thromboplastin time (aPTT): $30\text{ seconds}$ (Normal: $25-40\text{ seconds}$ )

A peripheral blood smear reveals numerous fragmented red blood cells.

Which of the following cellular or histologic processes most accurately describes the primary mechanism of hepatic injury in this patient?

Ischemic coagulative necrosis resulting from sinusoidal fibrin deposition

Centrilobular necrosis driven by free radical-mediated lipid peroxidation

Primary failure of hepatic coagulation factor synthesis leading to parenchymal hemorrhage

Widespread hepatocyte apoptosis mediated by CD8+ cytotoxic T lymphocytes

Microvesicular steatosis due to mitochondrial beta-oxidation dysfunction

Show answer & explanation

Answer: Ischemic coagulative necrosis resulting from sinusoidal fibrin deposition

Answer

Ischemic coagulative necrosis resulting from sinusoidal fibrin deposition

The correct answer identifies that the hepatic injury in HELLP syndrome is caused by ischemic coagulative necrosis resulting from sinusoidal fibrin deposition. Systemic endothelial injury leads to platelet activation and fibrin microthrombi formation. When these lodge in the hepatic sinusoids, they obstruct blood flow, resulting in focal ischemic necrosis, stretching of Glisson's capsule, and the characteristic right upper quadrant pain and elevated transaminases.

Step-by-Step Solution

Analyze the patient's clinical presentation.

The patient is a pregnant woman in the third trimester presenting with severe hypertension and right upper quadrant pain.

This establishes a differential diagnosis of pregnancy-related complications such as severe preeclampsia, HELLP syndrome, or Acute Fatty Liver of Pregnancy (AFLP).

Interpret the laboratory and peripheral smear findings.

Labs show a microangiopathic hemolytic anemia (anemia, schistocytes, elevated LDH and bilirubin), severe thrombocytopenia, elevated transaminases, and normal coagulation times (PT/aPTT).

These findings are required to confirm the specific diagnosis within the preeclampsia spectrum.

Synthesize the findings to establish a diagnosis.

The combination of Hemolysis, Elevated Liver enzymes, and Low Platelets with normal PT/aPTT definitively points to HELLP syndrome rather than AFLP or DIC.

Normal PT/aPTT distinguishes HELLP from AFLP and DIC, both of which typically present with consumptive coagulopathy and prolonged PT/aPTT.

Identify the primary cellular or histologic mechanism of hepatic injury for the diagnosed condition.

Systemic endothelial injury in HELLP syndrome leads to microvascular thrombosis and fibrin deposition in the hepatic sinusoids, causing focal ischemic coagulative necrosis.

This directly answers the prompt's question regarding the subcellular mechanism of the observed hepatic injury.

Key Concept

HELLP syndrome is characterized by systemic endothelial dysfunction leading to microangiopathic hemolytic anemia and the deposition of fibrin microthrombi in hepatic sinusoids, which subsequently causes ischemic coagulative necrosis of hepatocytes.

Question 85Question →

A $45$ -year-old woman comes to the ambulatory clinic complaining of a three-month history of worsening fatigue, a $4.5$ -kg ( $10$ -lb) weight gain, and new-onset constipation. Her vital signs include a temperature of $36.8^\circ$ C ( $98.2^\circ$ F), blood pressure of $118/76$ mmHg, and heart rate of $58$ /min. Physical examination reveals dry skin and delayed relaxation of the deep tendon reflexes. Laboratory testing shows a thyroid-stimulating hormone (TSH) level of $12.4$ mU/L (normal: $0.4-4.0$ mU/L) and a free thyroxine (T4) level of $0.6$ ng/dL (normal: $0.9-1.7$ ng/dL). The physician carefully reviews the patient's medical and medication history to determine the underlying cause of her presentation. Which of the following historical findings is the most likely etiology for this patient's current condition?

Long-term use of lithium carbonate for a psychiatric condition

Recent initiation of combined oral contraceptive pills

Regular consumption of over-the-counter St. John's wort

A viral upper respiratory tract infection two weeks ago

Family history of medullary thyroid carcinoma

Show answer & explanation

Answer: Long-term use of lithium carbonate for a psychiatric condition

Answer

Long-term use of lithium carbonate for a psychiatric condition

This patient exhibits classic signs and laboratory findings of primary hypothyroidism, specifically an elevated TSH and a low free T4, alongside fatigue, weight gain, delayed reflexes, and bradycardia. When evaluating the medical history for etiologies of new-onset primary hypothyroidism, a history of lithium carbonate use is a critical finding. Lithium inhibits the release of thyroid hormone from the thyroid gland and can lead to clinical hypothyroidism. For this reason, patients on long-term lithium therapy require routine monitoring of their thyroid function.

Step-by-Step Solution

Interpret the clinical and laboratory findings.

The patient has symptomatic bradycardia, weight gain, fatigue, an elevated TSH, and a low free T4.

These findings definitively establish the diagnosis of primary hypothyroidism.

Evaluate the medical history to identify potential etiologies for the established diagnosis.

Reviewing medication history is a critical step in working up new-onset primary hypothyroidism to identify iatrogenic causes.

Certain medications directly interfere with thyroid hormone synthesis or release.

Match the correct historical exposure to the pathophysiology of primary hypothyroidism.

Lithium carbonate is identified as the causal agent.

Lithium is a common drug that inhibits thyroid hormone release, necessitating routine TSH monitoring for patients on this therapy.

Key Concept

Medication-induced primary hypothyroidism (such as that caused by lithium or amiodarone) must be evaluated during the medical history review of a patient presenting with an elevated TSH and low free T4.

Question 86Question →

An internist is preparing hospital discharge orders for a $69$ -year-old male who was admitted four days ago for an acute exacerbation of heart failure. The patient has a known history of ischemic cardiomyopathy with a left ventricular ejection fraction of $25\%$ , type 2 diabetes mellitus, and stage 3 chronic kidney disease. Following successful intravenous diuresis, he is now euvolemic and breathing comfortably on room air.

Vital signs today show a blood pressure of $118/74$ mmHg and a heart rate of $72$ /min.

Current medications planned for discharge include:
- Lisinopril $20$ mg daily
- Carvedilol $12.5$ mg twice daily
- Dapagliflozin $10$ mg daily
- Oral torsemide $20$ mg daily

Laboratory results obtained this morning:

Test	Result
Sodium	$139$ mEq/L
Potassium	$4.3$ mEq/L
Blood urea nitrogen	$24$ mg/dL
Creatinine	$1.6$ mg/dL (baseline $1.5$ mg/dL)

To fully optimize guideline-directed medical therapy, the internist plans to prescribe spironolactone before the patient leaves the hospital.

Which of the following is the most appropriate action or instruction regarding the addition of this medication?

Initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

Advise the patient to replace dietary sodium with a potassium-enriched salt substitute.

Discontinue lisinopril to prevent the synergistic development of life-threatening hyperkalemia.

Defer initiation of the medication because the current serum creatinine level is an absolute contraindication.

Prescribe the medication and concurrently start daily naproxen to reduce the risk of diuretic-induced gout flares.

Show answer & explanation

Answer: Initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

Answer

The most appropriate action is to initiate the medication and arrange for a follow-up basic metabolic panel in one to two weeks.

The correct answer involves initiating the medication and scheduling a follow-up metabolic panel in one to two weeks. Mineralocorticoid receptor antagonists (MRAs) such as spironolactone provide a significant mortality benefit in patients with heart failure with reduced ejection fraction (HFrEF). However, because they are potassium-sparing diuretics, their use carries a substantial risk of hyperkalemia and worsening renal function. This risk is heavily amplified in patients with underlying chronic kidney disease and those concurrently taking ACE inhibitors (like lisinopril), ARBs, or ARNIs. Therefore, clinical guidelines strongly recommend checking serum potassium and renal function within

1

2

weeks after initiating an MRA or increasing its dose to prevent life-threatening hyperkalemia.

Step-by-Step Solution

Identify the patient's underlying conditions and current status.

The patient has heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease, and is currently euvolemic on a regimen of lisinopril, carvedilol, dapagliflozin, and torsemide.

Establishing the clinical baseline is necessary to determine what guideline-directed therapies are missing and what risks they may pose.

Evaluate the safety and indications for adding spironolactone.

Spironolactone is a mineralocorticoid receptor antagonist (MRA) indicated for HFrEF to reduce mortality. The patient's creatinine (

1.6

mg/dL) and potassium (

4.3

mEq/L) are within safe parameters for initiation.

MRAs are contraindicated in severe renal failure or baseline hyperkalemia, so lab values must be verified before prescribing.

Determine the necessary follow-up protocol for the new medication.

Guidelines mandate checking a basic metabolic panel within

1

2

weeks of starting an MRA.

The combination of an MRA, an ACE inhibitor (lisinopril), and baseline chronic kidney disease significantly elevates the risk of acute hyperkalemia and renal dysfunction, requiring prompt surveillance.

Key Concept

Initiation of mineralocorticoid receptor antagonists in heart failure requires close laboratory monitoring of potassium and renal function, typically within 1 to 2 weeks, due to the risk of hyperkalemia, especially when co-administered with ACE inhibitors.

Question 87Question →

A 34-year-old man with a history of intravenous drug use is admitted to the hospital with fever, chills, and pleuritic chest pain. Blood cultures grow *Staphylococcus aureus* resistant to oxacillin but susceptible to vancomycin. Echocardiography reveals a 1.4-cm mobile vegetation on the tricuspid valve. He is started on intravenous vancomycin. Over the next two weeks, the patient remains persistently febrile, and surveillance blood cultures continue to yield *S. aureus*. Susceptibility testing shows the minimum inhibitory concentration (MIC) for vancomycin has increased from 1.0 to 4.0 mcg/mL. The patient's antimicrobial regimen is changed to a cyclic lipopeptide agent that binds to the bacterial cell membrane in a calcium-dependent manner, leading to rapid depolarization and cell death. The patient shows initial clinical improvement, but four weeks later, he presents again with fever and recurrent bacteremia with the same organism. Susceptibility testing now reveals resistance to the newly added cyclic lipopeptide agent. Which of the following molecular events best explains the organism's acquired resistance to the second-line antimicrobial agent?

Addition of L-lysine to phosphatidylglycerol within the cell membrane

Reprogramming of peptidoglycan termini from D-alanyl-D-alanine to D-alanyl-D-lactate

Synthesis of a thickened cell wall with increased numbers of decoy binding sites

Point mutation in the 23S ribosomal RNA of the 50S subunit

Enzymatic inactivation of the drug via a plasmid-encoded acetyltransferase

Show answer & explanation

Answer: Addition of L-lysine to phosphatidylglycerol within the cell membrane

Answer

Addition of L-lysine to phosphatidylglycerol within the cell membrane

The patient initially failed vancomycin therapy due to reduced susceptibility (Vancomycin-Intermediate S. aureus, or VISA) and was subsequently switched to daptomycin. Daptomycin is a cyclic lipopeptide antibiotic that inserts into the bacterial cell membrane in a calcium-dependent manner, causing rapid depolarization, potassium efflux, and cell death. Resistance to daptomycin in S. aureus typically occurs through gain-of-function mutations in the multiple peptide resistance factor (mprF) gene. The MprF protein is an enzyme that adds positively charged L-lysine molecules to membrane phosphatidylglycerol, creating lysyl-phosphatidylglycerol. This modification neutralizes the normally negative net surface charge of the bacterial membrane, shifting it to a more positive charge. Because the active daptomycin-calcium complex is also positively charged, the altered membrane electrostatically repels the drug, preventing its insertion and subsequent cell death.

Step-by-Step Solution

Identify the cause of the initial treatment failure.

The vancomycin MIC increased to 4.0 mcg/mL, indicating the development of Vancomycin-Intermediate S. aureus (VISA).

Recognizing the initial failure helps establish the context for the subsequent drug switch.

Identify the second-line antimicrobial agent based on its mechanism of action.

The agent is daptomycin, a cyclic lipopeptide that causes calcium-dependent membrane depolarization.

Knowing the specific drug is necessary to determine its unique resistance mechanisms.

Determine the molecular mechanism of resistance to daptomycin in S. aureus.

Resistance occurs via mutations in the mprF gene, leading to the addition of L-lysine to phosphatidylglycerol.

This specific alteration changes the membrane charge, directly answering the question.

Key Concept

The primary mechanism of daptomycin resistance in Staphylococcus aureus involves mutations in the mprF gene, which alter the cell membrane charge to repel the calcium-bound drug complex.

Question 88Question →

Match each clinical scenario involving an emergent or highly drug-resistant infection to the precise molecular mechanism responsible for its antimicrobial resistance profile.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The accurate molecular resistance pairings are: C. glabrata (micafungin resistance) with FKS1/FKS2 mutations; N. gonorrhoeae (ceftriaxone resistance) with mosaic penA alleles; A. fumigatus (environmental azole resistance) with cyp51A TR34/L98H mutations; K. pneumoniae (ceftazidime-avibactam resistance / imipenem susceptibility) with KPC omega loop mutations; and M. tuberculosis (bedaquiline/clofazimine resistance) with Rv0678 efflux pump upregulation.

Each pathogen-phenotype pair maps exclusively to a specific genetic alteration. FKS mutations disrupt echinocandin binding in Candida. Mosaic penA structural changes prevent ceftriaxone binding in Neisseria. The TR34/L98H cyp51A mutation is the hallmark of environmentally acquired azole resistance in Aspergillus. KPC omega-loop mutations uniquely enhance ceftazidime hydrolysis while sacrificing carbapenemase activity. Finally, Rv0678 mutations in MTB upregulate the MmpS5-MmpL5 efflux pump, creating dual resistance to bedaquiline and clofazimine.

Step-by-Step Solution

Analyze each clinical vignette to identify the pathogen and the specific antimicrobial resistance phenotype described.

Identified pathogens include C. glabrata, N. gonorrhoeae, A. fumigatus, K. pneumoniae, and M. tuberculosis, each with specific drug failures.

Establishing the organism-drug pair is essential to determining the molecular target of resistance.

Map the antimicrobial drug class to its cellular target.

Micafungin targets beta-glucan synthase. Ceftriaxone targets PBPs. Azoles target lanosterol 14-alpha-demethylase. Ceftazidime-avibactam targets cell wall synthesis while inhibiting beta-lactamases. Bedaquiline targets mycobacterial ATP synthase, but shares efflux pathways.

Understanding the drug's mechanism of action restricts the possible mechanisms of resistance.

Correlate the specific genetic mutation to the biochemical change that confers the resistance phenotype.

FKS mutations alter beta-glucan synthase; mosaic penA alters PBP2; cyp51A mutations alter ergosterol synthesis; KPC omega loop mutations alter beta-lactamase specificity; Rv0678 mutations upregulate generalized efflux pumps.

This confirms the precise mechanistic pairings required to solve the matching problem.

Key Concept

Molecular mechanisms of advanced antimicrobial resistance in emergent pathogens

Question 89Question →

A 68-year-old man is evaluated in the hospital on the third day of admission for community-acquired pneumonia. He was initially started on intravenous ceftriaxone and azithromycin. The patient reports feeling significantly better, with a marked decrease in his cough and complete resolution of his shortness of breath. He has been afebrile for the past $24$ hours and is tolerating a regular diet without difficulty.

Vital signs are:
Temperature: $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ )
Blood pressure: $126/78\text{ mm Hg}$
Heart rate: $78/\text{min}$
Respiratory rate: $14/\text{min}$
Oxygen saturation: $96\%$ on room air

Laboratory studies show a leukocyte count of $8,500/\mu\text{L}$ , which has decreased from $15,200/\mu\text{L}$ on admission. A chest radiograph obtained this morning demonstrates a persistent right lower lobe consolidation, which is unchanged compared to the admission radiograph.

Which of the following is the most appropriate next step in management?

Broaden the antibiotic regimen to include coverage for methicillin-resistant *Staphylococcus aureus*

Continue intravenous antibiotics until the chest radiograph shows clearance of the consolidation

Transition to an oral antibiotic regimen and arrange for hospital discharge

Obtain a computed tomography scan of the chest to evaluate for underlying malignancy

Perform a diagnostic bronchoscopy with bronchoalveolar lavage

Show answer & explanation

Answer: Transition to an oral antibiotic regimen and arrange for hospital discharge

Answer

The most appropriate step is to transition the patient to an oral antibiotic regimen and arrange for hospital discharge.

The patient has community-acquired pneumonia and is demonstrating an excellent clinical response to empiric antibiotic therapy. He meets all standardized criteria for clinical stability: he is afebrile, hemodynamically stable, has a normal respiratory rate and oxygen saturation, and is able to maintain oral intake. Once clinical stability is achieved (usually within 48 to 72 hours), patients should be transitioned from intravenous to oral antibiotics and discharged home to complete their treatment course. The persistence of the lung consolidation on the repeat chest radiograph is a normal and expected finding. Radiographic resolution of pneumonia significantly lags behind clinical improvement and can take up to 6 to 12 weeks. Therefore, treatment de-escalation and hospital discharge should be guided entirely by clinical criteria rather than radiographic findings.

Step-by-Step Solution

Evaluate the patient's clinical response to the current empiric antibiotic therapy.

The patient is afebrile, hemodynamically stable, breathing comfortably on room air, and tolerating an oral diet. This indicates excellent clinical stability and treatment success.

Determining clinical stability is the critical first step in deciding whether to de-escalate therapy or prepare for discharge.

Interpret the chest radiograph findings in the context of the patient's clinical improvement.

The persistent right lower lobe consolidation is an expected finding. Radiographic resolution of pneumonia lags behind clinical resolution by several weeks.

Misinterpreting a normal delay in radiographic clearing as treatment failure can lead to inappropriate and potentially harmful management decisions.

Determine the optimal management plan based on the assessment.

Transition to oral antibiotics and arrange for safe discharge home.

Once clinical stability is reached on intravenous antibiotics, promptly transitioning to oral therapy and discharging the patient minimizes hospital length of stay and reduces the risk of nosocomial complications.

Key Concept

In patients with community-acquired pneumonia, radiographic resolution significantly lags behind clinical improvement; discharge decisions should be based on clinical stability criteria, not on the clearance of infiltrates on a chest radiograph.

Estimated Time:1m 0s

Question 90Question →

A 52-year-old man comes to the clinic for an urgent evaluation due to new-onset hand tremors and worsening headaches over the past three days. He underwent a deceased-donor renal transplantation eight months ago for end-stage renal disease secondary to polycystic kidney disease. His maintenance immunosuppression regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Two weeks ago, he was seen at a local urgent care clinic for a sore throat and thick, white, scrapable plaques on his tongue and buccal mucosa. He was prescribed a 14-day course of an oral medication for this condition. Today, his temperature is 37.1°C (98.8°F), blood pressure is 158/92 mm Hg, and pulse is 88/min. Physical examination is notable for a fine resting tremor in both hands. Laboratory studies reveal a serum creatinine of 2.4 mg/dL, which is significantly elevated from his baseline of 1.3 mg/dL measured one month ago. Which of the following medications was most likely prescribed at the urgent care clinic?

Acyclovir

Clindamycin

Fluconazole

Nystatin

Terbinafine

Show answer & explanation

Answer: Fluconazole

Answer

Fluconazole

The correct answer is the oral triazole antifungal, fluconazole. The patient's initial presentation of thick, white, scrapable plaques on the oral mucosa is diagnostic of oropharyngeal candidiasis (oral thrush), a common opportunistic infection in solid organ transplant recipients on maintenance immunosuppression. His current symptoms of acute kidney injury (elevated creatinine), new-onset tremors, headache, and hypertension are hallmark features of calcineurin inhibitor (tacrolimus) toxicity. Tacrolimus is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system. Fluconazole is a potent inhibitor of CYP3A4. When fluconazole is coadministered with tacrolimus, it significantly impairs tacrolimus clearance, leading to elevated systemic trough levels and subsequent nephrotoxicity and neurotoxicity. In clinical practice, if systemic azole therapy is required in a patient on a calcineurin inhibitor, empirical preemptive dose reduction of the calcineurin inhibitor and close therapeutic drug monitoring are mandatory.

Step-by-Step Solution

Diagnose the antecedent condition described as thick, white, scrapable plaques on the oral mucosa.

The clinical description is highly specific for oropharyngeal candidiasis (oral thrush), an opportunistic fungal infection common in immunosuppressed patients.

Identifying the initial infection is necessary to determine which class of medication was prescribed at the urgent care clinic.

Identify the cause of the patient's current symptoms (tremors, headache, hypertension, and acute kidney injury).

The presentation is classic for calcineurin inhibitor (tacrolimus) toxicity.

Tacrolimus has a narrow therapeutic index; elevated serum levels cause prominent nephrotoxicity and neurotoxicity.

Determine which treatment for oral candidiasis precipitates tacrolimus toxicity.

Fluconazole.

Tacrolimus is extensively metabolized by the hepatic and intestinal cytochrome P450 3A4 (CYP3A4) system. Systemic azole antifungals, such as fluconazole, are potent inhibitors of CYP3A4, leading to decreased tacrolimus clearance and subsequent toxicity.

Key Concept

Pharmacokinetic interactions of CYP3A4 inhibitors with calcineurin inhibitors

Estimated Time:1m 15s

Question 91Question →

Paramedics bring a 58-year-old woman to the emergency department after her husband witnessed her suddenly collapse and begin shaking. Upon arrival in the resuscitation bay, she is actively experiencing a generalized tonic-clonic seizure. Her husband states the seizure activity has been continuous for approximately 15 minutes without any return to consciousness. She has no known past medical history and takes no daily medications. Vital signs show a blood pressure of 145/90 mmHg, heart rate of 118/min, and oxygen saturation of 94% on a non-rebreather mask. Intravenous access is rapidly established by the nursing staff, and a point-of-care blood glucose level is 102 mg/dL.

Arrange the following pharmacologic interventions in the correct sequential order for the management of this patient's condition, starting from the most immediate initial therapy to the final step for super-refractory disease.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is: 1) Administer intravenous lorazepam, 2) Administer intravenous fosphenytoin, 3) Initiate a continuous intravenous propofol infusion, 4) Initiate a continuous intravenous pentobarbital infusion.

The management of status epilepticus follows a strict time-based protocol. The initial therapy phase (0-20 minutes) requires a rapid-acting benzodiazepine such as intravenous lorazepam. This is followed by the second therapy phase (20-40 minutes), which utilizes a non-benzodiazepine antiseizure medication such as fosphenytoin to achieve sustained control. If clinical or electrographic seizures continue, the patient enters refractory status epilepticus (40-60 minutes), necessitating intubation and continuous intravenous anesthetic infusions such as propofol. Finally, if seizures persist despite general anesthesia for 24 hours or more, it is termed super-refractory status epilepticus, and profound barbiturate coma with pentobarbital or thiopental is indicated as a last resort.

Step-by-Step Solution

Identify the clinical emergency and the current duration of the event.

The patient is in generalized convulsive status epilepticus (continuous seizure >5 minutes, currently at 15 minutes).

Accurate diagnosis and timing dictate the specific phase of the treatment algorithm.

Select the first-line pharmacologic intervention.

Intravenous lorazepam is administered immediately.

Benzodiazepines are the most rapid and effective agents for acutely halting seizure activity in the initial phase (5-20 minutes).

Select the second-line pharmacologic intervention.

Intravenous fosphenytoin (or levetiracetam/valproic acid) is administered.

A long-acting non-benzodiazepine antiseizure medication must be given to prevent recurrence or to treat seizures that do not respond to the initial benzodiazepine (20-40 minute phase).

Determine the approach for refractory and super-refractory cases.

Propofol is used for refractory cases, followed by pentobarbital if super-refractory.

Anesthetic infusions like propofol or midazolam are used when standard agents fail. Pentobarbital induces a deep barbiturate coma and is strictly a last resort due to its severe hemodynamic side effects.

Key Concept

The stepwise, time-dependent pharmacologic management algorithm for generalized convulsive status epilepticus.

Question 92Question →

A $65$ -year-old man is brought to the emergency department by emergency medical services after collapsing at an airport following a $14$ -hour international flight. He has a history of end-stage renal disease and receives hemodialysis three times a week. On arrival, he is in severe respiratory distress, confused, and diaphoretic.

Vital signs are as follows:
- Temperature: $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ )
- Heart rate: $135\text{/min}$
- Blood pressure: $72/40\text{ mmHg}$
- Respiratory rate: $32\text{/min}$
- Oxygen saturation: $82\%$ on room air

Physical examination reveals marked jugular venous distention and cyanosis of the distal extremities. Pulmonary auscultation is clear bilaterally. The physician suspects a massive pulmonary embolism causing acute obstructive shock.

Arrange the following diagnostic and therapeutic management steps in the most appropriate chronological sequence for this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing massive pulmonary embolism with hemodynamic instability in this patient begins with ABC stabilization, followed by hemodynamic support with vasopressors, bedside echocardiography for diagnosis, unfractionated heparin for anticoagulation (due to ESRD), and finally systemic thrombolysis.

The sequence for managing a massive pulmonary embolism begins with life-saving ABCs and hemodynamic support. Because the patient is unstable, transporting him for a CT pulmonary angiogram is contraindicated; therefore, bedside echocardiography is the appropriate next step to demonstrate right ventricular strain. Once confirmed, systemic anticoagulation is initiated. Notably, because this patient has end-stage renal disease, unfractionated heparin must be used instead of low-molecular-weight heparin to prevent drug accumulation and bleeding. Finally, definitive reperfusion with systemic thrombolytics (alteplase) is administered to dissolve the clot and relieve the obstructive shock.

Step-by-Step Solution

Administer high-flow supplemental oxygen and establish large-bore intravenous access.

Hypoxemia is addressed and a route for emergency medications is secured.

Securing the airway and providing supplemental oxygen mitigates hypoxic pulmonary vasoconstriction, which would otherwise worsen right ventricular strain.

Initiate intravenous vasopressor therapy to target a mean arterial pressure

> 65\text{ mmHg}

Perfusion to vital organs, including the coronary arteries, is maintained.

Hypotension in massive pulmonary embolism rapidly leads to right ventricular ischemia and cardiovascular collapse; immediate hemodynamic support is essential.

Perform bedside point-of-care echocardiography to evaluate for right ventricular dysfunction.

Right ventricular dilation and hypokinesis are identified.

An unstable patient cannot safely travel to a CT scanner. Point-of-care echocardiography is the diagnostic modality of choice to confirm the suspected diagnosis.

Initiate systemic anticoagulation with intravenous unfractionated heparin.

Further propagation of the thromboembolism is halted.

Systemic anticoagulation must be initiated promptly. Low-molecular-weight heparins (like enoxaparin) are contraindicated in end-stage renal disease, necessitating the use of unfractionated heparin.

Administer intravenous alteplase for definitive systemic thrombolytic therapy.

The pulmonary arterial clot burden is rapidly reduced, restoring forward blood flow.

Once right heart strain is confirmed and baseline anticoagulation is addressed, thrombolytics are administered to break down the existing clot and resolve the obstructive shock.

Key Concept

Management of massive pulmonary embolism involves immediate stabilization, bedside echocardiography, and systemic thrombolysis, with unfractionated heparin preferred over low-molecular-weight heparin in patients with severe renal impairment.

Estimated Time:1m 30s

Question 93Question →

Match the following specific patient environmental or occupational exposures obtained during the medical history with the most likely corresponding infectious disease diagnosis to consider.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Cave exploration in the Ohio River Valley matches Histoplasmosis; Abattoir work matches Brucellosis; Hiking in Connecticut with a tick bite matches Lyme disease; Cleaning a mouse-infested barn in the Southwest US matches Hantavirus pulmonary syndrome.

Each specific exposure elicited in the patient's medical history uniquely predisposes them to a particular infectious agent based on geography and environmental conditions. Gathering these precise historical details is a foundational step in establishing an accurate diagnosis.

Step-by-Step Solution

Analyze the geographical and environmental exposure for the first history element.

Cave exploration in the Ohio River Valley points to exposure to bat droppings in a known endemic area.

Identifying specific endemic fungi associated with caves is crucial for diagnosing Histoplasmosis.

Analyze the occupational exposure for the second history element.

Abattoir work involves direct occupational exposure to livestock tissues.

Brucellosis is a known occupational hazard for those handling infected animal tissues.

Analyze the geographical and vector exposure for the third history element.

Hiking in Connecticut (Northeast US) with a tick bite is the classic risk factor for acquiring Lyme disease.

Recognizing the endemic region and vector for Borrelia burgdorferi establishes the diagnosis.

Analyze the environmental exposure for the fourth history element.

Cleaning a mouse-infested barn in the Southwest US involves aerosolized rodent droppings.

Sin Nombre virus (Hantavirus) is transmitted through aerosolized deer mouse droppings in this specific geographic region.

Key Concept

Identifying specific environmental, geographic, and occupational exposures during a medical history is essential for prioritizing the differential diagnosis for infectious diseases.

Question 94Question →

Match each clinical scenario describing a targeted immunomodulatory therapy to its direct foundational immunopathologic consequence or the mechanism of its signature adverse effect.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct pairings link specific immunomodulatory mechanisms to their downstream cellular consequences: CTLA-4 inhibition with disrupted peripheral tolerance, VLA-4 blockade with impaired CNS transmigration, IL-5 neutralization with eosinophil depletion, terminal complement inhibition with MAC failure, and TNF-alpha decoy receptors with granuloma breakdown.

Each therapy targets a distinct immunologic pathway. Anti-CTLA-4 prevents the inhibitory signal in the immunological synapse, causing autoimmunity. VLA-4 blockade stops integrin-mediated firm adhesion, preventing CNS immunosurveillance. Anti-IL-5 removes the survival signal for eosinophils. C5 inhibition stops the membrane attack complex. TNF-alpha decoy receptors remove the macrophage-activating signal necessary for granuloma integrity.

Step-by-Step Solution

Analyze the first clinical vignette describing a therapy that prevents CD28 outcompetition.

Identify this as an anti-CTLA-4 agent.

CTLA-4 normally downregulates T-cell activation by outcompeting CD28 for B7 ligands on APCs. Blocking it disrupts peripheral tolerance, leading to hypophysitis.

Examine the second vignette detailing VLA-4 and VCAM-1 blockade.

Identify this as natalizumab, which prevents firm adhesion of leukocytes.

Without firm adhesion, T-cells cannot cross the blood-brain barrier, leading to risk of JC virus reactivation (PML).

Evaluate the third vignette describing neutralization of a Th2 differentiation factor in asthma.

Identify the factor as IL-5 and the therapy as an anti-IL-5 biologic.

IL-5 is essential for eosinophil survival; eosinophils utilize major basic protein against helminths.

Identify the complement inhibitor in the fourth vignette.

Recognize the C5 inhibitor eculizumab.

Blocking C5 prevents MAC formation, making the patient susceptible to Neisseria species.

Assess the fifth vignette describing a receptor-Fc fusion protein in rheumatoid arthritis.

Identify etanercept, a TNF-alpha inhibitor.

TNF-alpha is crucial for macrophage activation and granuloma maintenance, risking tuberculosis reactivation when inhibited.

Key Concept

The immunopathologic consequences of targeted biologic therapies are directly related to the specific cellular interactions, receptor bindings, and cytokine pathways they inhibit.

Question 95Question →

During morning rounds in the intensive care unit, the medical team evaluates a patient receiving treatment for an acute massive pulmonary embolism. The 58-year-old male, who has a documented history of advanced chronic kidney disease (stage G4), was started on a continuous intravenous unfractionated heparin infusion upon admission. Which of the following laboratory parameters must be routinely monitored to ensure the efficacy and safety of this specific anticoagulant therapy? (Select all that apply)

Select all that apply

Activated partial thromboplastin time (aPTT)

Platelet count

International Normalized Ratio (INR)

Serum creatinine

D-dimer

Show answer & explanation

Answer: Activated partial thromboplastin time (aPTT); Platelet count

Answer

The correct parameters to monitor are the Activated partial thromboplastin time (aPTT) and the Platelet count.

The correct answers identify the aPTT and platelet count as essential monitoring parameters. Unfractionated heparin primarily affects the intrinsic coagulation pathway, meaning its therapeutic efficacy must be titrated using the aPTT (or anti-factor Xa levels). Additionally, unfractionated heparin carries a significant risk of heparin-induced thrombocytopenia (HIT), necessitating serial monitoring of the platelet count to promptly identify sudden drops that indicate this dangerous immune-mediated reaction.

Step-by-Step Solution

Identify the primary medication and its pharmacokinetic profile.

The patient is receiving a continuous intravenous infusion of unfractionated heparin.

Different anticoagulants target different parts of the coagulation cascade and have distinct clearance and adverse effect profiles.

Determine the necessary efficacy monitoring parameter for this specific drug.

Activated partial thromboplastin time (aPTT) is selected.

Unfractionated heparin inhibits factors IIa and Xa, affecting the intrinsic pathway, which is measured by aPTT to ensure the infusion dose is within the therapeutic window.

Determine the necessary safety monitoring parameter unique to this specific drug.

Platelet count is selected.

Unfractionated heparin carries a high risk of causing heparin-induced thrombocytopenia (HIT), requiring serial platelet count monitoring to detect potentially catastrophic immune-mediated drops in platelets.

Key Concept

Monitoring Unfractionated Heparin Therapy

Question 96Question →

Match the following clinical vignettes, which describe distinct forms of cellular injury or adaptation, with their precise underlying pathophysiologic mechanisms.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The myocardial reperfusion vignette matches calcium-mediated sarcomere hypercontraction. The cast immobilization vignette matches targeted degradation of cytoskeletal proteins via ubiquitin ligases. The lupus nephritis vignette matches deposition of immune complexes and plasma proteins. The ischemic stroke vignette matches extensive release of hydrolytic enzymes causing tissue dissolution.

The correct pairings accurately link distinct clinical presentations to their fundamental cellular mechanisms. The myocardial reperfusion scenario is classically characterized by contraction band necrosis due to massive calcium influx. The immobilized limb scenario represents disuse atrophy driven by the ubiquitin-proteasome pathway. The lupus nephritis scenario describes fibrinoid necrosis, where immune complexes deposit in blood vessel walls. Finally, the remote ischemic stroke scenario illustrates liquefactive necrosis, which uniquely occurs in the brain following hypoxic injury due to rapid enzymatic digestion.

Step-by-Step Solution

Analyze the myocardial infarction presentation with post-intervention arrhythmias and eosinophilic bands.

Identify this as contraction band necrosis secondary to reperfusion injury.

Reperfusion restores oxygen and calcium to damaged cells, triggering massive reactive oxygen species generation and calcium influx that forces sarcomeres into hypercontraction.

Evaluate the localized muscle wasting following prolonged cast immobilization.

Identify this as disuse atrophy.

Lack of mechanical stress induces the ubiquitin-proteasome pathway to degrade cellular proteins, reducing cell size to match the diminished metabolic demand.

Examine the renal biopsy findings in a young woman with systemic lupus erythematosus.

Identify this as fibrinoid necrosis of the arterioles.

Type III hypersensitivity reactions cause immune complex deposition in vessel walls, allowing plasma proteins like fibrin to leak, which appears as amorphous eosinophilic material.

Interpret the remote CNS imaging showing a fluid-filled cavity months after an ischemic event.

Identify this as the end-stage of liquefactive necrosis.

The brain lacks substantial supporting connective tissue stroma; therefore, hypoxic cell death triggers rapid enzymatic digestion by microglial cells rather than preservation of cellular architecture.

Key Concept

Distinct forms of cellular injury (e.g., reperfusion injury, liquefactive necrosis, fibrinoid necrosis) and adaptation (e.g., atrophy) are driven by specific biochemical mechanisms tailored to the tissue type and etiologic trigger.

Estimated Time:1m 30s

Question 97Question →

A 72-year-old man with a history of severe rheumatoid arthritis is brought to the emergency department due to progressive swelling and severe pain in his right thigh over the past 48 hours. He denies any recent trauma, surgery, or changes to his medications. His current medications include methotrexate and prednisone. Vital signs show a blood pressure of 105/65 mm Hg and a heart rate of 112/min. Physical examination reveals a massive, tense, ecchymotic swelling extending from the right groin to the knee. Laboratory studies show:

Test	Result	Reference Range
Hemoglobin	7.2 g/dL	13.5-17.5 g/dL
Platelet count	210,000/mm³	150,000-400,000/mm³
Prothrombin time (PT)	12 sec	11-15 sec
Activated partial thromboplastin time (aPTT)	94 sec	25-40 sec

A mixing study is performed using a 1:1 mixture of the patient's plasma and normal pooled plasma. Immediately after mixing, the aPTT is 34 seconds. After incubating the mixture at $37^\circ\text{C}$ for 2 hours, the aPTT is 82 seconds.

Which of the following describes the mechanism of action of the most appropriate immediate hemostatic pharmacotherapy for this patient?

Complexing with exposed tissue factor to independently catalyze the conversion of factor X to factor Xa

Direct replacement of the deficient glycoprotein to competitively overcome autoantibody neutralization

Stimulation of endothelial Weibel-Palade bodies to release stored endogenous coagulation factors

Bispecific bridging of activated factor IX and factor X to restore the intrinsic tenase complex

Provision of a concentrated cryoprecipitate containing high levels of fibrinogen and factor VIII

Show answer & explanation

Answer: Complexing with exposed tissue factor to independently catalyze the conversion of factor X to factor Xa

Answer

Recombinant factor VIIa (rFVIIa), which complexes with exposed tissue factor to independently catalyze the conversion of factor X to factor Xa.

The correct answer identifies the mechanism of recombinant factor VIIa (rFVIIa). This patient's presentation of spontaneous severe bleeding in the setting of an autoimmune disease (rheumatoid arthritis), combined with an isolated prolonged aPTT that corrects immediately but prolongs after incubation, is diagnostic of acquired hemophilia A (Factor VIII autoantibodies). Because the inhibitor is time- and temperature-dependent, the autoantibodies will rapidly neutralize standard factor VIII replacement. Therefore, acute severe bleeding must be managed with a 'bypassing agent' such as rFVIIa or activated prothrombin complex concentrate (aPCC). rFVIIa works by complexing with tissue factor at the site of vascular injury to directly catalyze the conversion of factor X to factor Xa, bypassing the blocked intrinsic tenase complex (Factor IXa + Factor VIIIa).

Step-by-Step Solution

Analyze the basic coagulation panel.

The patient has an isolated, markedly prolonged aPTT with a normal PT and normal platelet count.

This isolates the defect to the intrinsic coagulation pathway (factors VIII, IX, XI, or XII).

Interpret the mixing study results.

The aPTT corrects immediately upon mixing but becomes prolonged again after a 2-hour incubation at

37^\circ\text{C}

This is the hallmark of a time- and temperature-dependent inhibitor, specifically an autoantibody against Factor VIII, confirming a diagnosis of acquired hemophilia A.

Determine the optimal acute management for severe bleeding in this condition.

Standard factor replacement will be rapidly neutralized. A bypassing agent is required.

The patient has life-threatening hemorrhage (massive thigh hematoma, hemoglobin 7.2 g/dL) requiring immediate bypass of the inhibited intrinsic tenase complex.

Identify the mechanism of action of the bypassing agent.

Recombinant factor VIIa (rFVIIa) or activated prothrombin complex concentrate (aPCC) must be used.

rFVIIa forms a complex with tissue factor at the site of vascular injury to directly activate factor X, bypassing the need for factor VIIIa altogether.

Key Concept

Acquired hemophilia A is characterized by an isolated prolonged aPTT that corrects on immediate mixing but prolongs after incubation; acute severe bleeding is treated with bypassing agents (rFVIIa or aPCC) which activate factor X independently of the intrinsic tenase complex.

Question 98Question →

A 4-year-old girl is brought to the pediatric urgent care clinic by her parents due to a two-day history of bloody diarrhea, severe abdominal cramping, and low-grade fever. The family recently visited a local dairy farm. Laboratory tests reveal microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Stool culture isolates a Gram-negative bacillus that ferments lactose but does not ferment sorbitol. The primary virulence factor responsible for this patient's systemic complications causes cellular damage through which of the following molecular mechanisms?

ADP-ribosylation of elongation factor-2 to halt polypeptide chain elongation

Constitutive activation of adenylate cyclase leading to a massive efflux of chloride and water

Removal of a specific adenine base from the 28S ribosomal RNA of the 60S subunit

Zinc metalloprotease cleavage of SNARE proteins to inhibit vesicular fusion

Hydrolysis of host cell membrane lecithin resulting in extensive cellular lysis

Show answer & explanation

Answer: Removal of a specific adenine base from the 28S ribosomal RNA of the 60S subunit

Answer

Removal of a specific adenine base from the 28S ribosomal RNA of the 60S subunit

The patient's presentation of bloody diarrhea followed by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury is classic for Hemolytic Uremic Syndrome (HUS). The stool culture isolation of a Gram-negative bacillus that ferments lactose but fails to ferment sorbitol confirms the diagnosis of Enterohemorrhagic Escherichia coli (EHEC) O157:H7 infection. EHEC causes systemic damage primarily through the elaboration of Shiga-like toxin (Verotoxin). Once inside the host endothelial cells, the A subunit of this toxin acts as an RNA N-glycosidase. It specifically removes a single adenine base from the 28S ribosomal RNA of the 60S ribosomal subunit. This depurination prevents the binding of aminoacyl-tRNA to the ribosome, irreversibly halting protein synthesis and leading to endothelial cell death. This endothelial damage initiates the widespread microthrombi formation characteristic of HUS.

Step-by-Step Solution

Identify the clinical syndrome and likely pathogen from the patient's presentation.

The combination of bloody diarrhea followed by hemolytic anemia, thrombocytopenia, and acute kidney injury indicates Hemolytic Uremic Syndrome (HUS). The stool culture finding of a lactose-fermenting, sorbitol-non-fermenting Gram-negative bacillus identifies Enterohemorrhagic Escherichia coli (EHEC) O157:H7.

Correctly identifying the pathogen is required to determine the specific virulence factor involved.

Identify the primary virulence factor produced by EHEC that causes systemic complications.

EHEC produces Shiga-like toxin (Verotoxin), which enters the bloodstream and damages the endothelium, leading to HUS.

The severe systemic complications (HUS) are toxin-mediated rather than being caused by bacterial invasion of the bloodstream.

Recall the precise molecular mechanism of Shiga-like toxin.

The A subunit of Shiga-like toxin acts as an N-glycosidase, cleaving a specific adenine residue from the 28S rRNA of the host's 60S ribosomal subunit.

This enzymatic action prevents the binding of aminoacyl-tRNA, irreversibly halting host protein synthesis and causing endothelial cell death.

Key Concept

Enterohemorrhagic Escherichia coli (EHEC) produces Shiga-like toxin, which causes Hemolytic Uremic Syndrome (HUS) by inactivating the 60S ribosomal subunit through the removal of a specific adenine residue from the 28S rRNA, halting host cell protein synthesis.

Question 99Question →

A $76$ -year-old woman comes to the outpatient clinic for a routine follow-up. Two weeks ago, she was diagnosed with major depressive disorder, and she is agreeable to starting pharmacotherapy today. A prescription for sertraline is initiated. Her medical history includes essential hypertension, hyperlipidemia, and osteoarthritis. Her daily medications include hydrochlorothiazide, lisinopril, atorvastatin, and as-needed acetaminophen. Her blood pressure is $135/82\text{ mmHg}$ and her heart rate is $74\text{/min}$ . Physical examination is unremarkable. In addition to assessing her clinical response to the new medication, which of the following is the most appropriate monitoring plan for this patient?

Measure serum sodium concentration in

2

4

weeks

Measure serum potassium concentration in

1

week

Obtain an electrocardiogram in

4

weeks

Measure serum aminotransferase levels in

4

weeks

Measure serum thyroid-stimulating hormone in

6

weeks

Show answer & explanation

Answer: Measure serum sodium concentration in $2$ to $4$ weeks

Answer

Measure serum sodium concentration in 2 to 4 weeks.

The correct action is to measure the serum sodium concentration. Elderly patients are at an increased risk of developing the syndrome of inappropriate antidiuretic hormone secretion (SIADH) when treated with selective serotonin reuptake inhibitors (SSRIs) such as sertraline. This risk is significantly magnified when the patient is concurrently taking a thiazide diuretic (e.g., hydrochlorothiazide), which independently depletes sodium. Current clinical guidelines recommend checking a basic metabolic panel for serum sodium levels

2

4

weeks after initiating an SSRI in older adults, particularly those with interacting medications or baseline risk factors.

Step-by-Step Solution

Analyze the patient's demographic profile and current medication regimen.

The patient is a

76

-year-old woman taking a thiazide diuretic (hydrochlorothiazide) who is starting a selective serotonin reuptake inhibitor (SSRI).

Age and polypharmacy significantly increase the risk of specific adverse drug events.

Identify the primary pharmacological risks associated with the new medication (sertraline).

SSRIs are strongly associated with the development of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).

SIADH leads to euvolemic hyponatremia, which can cause severe neurologic complications in the elderly.

Determine compounding synergistic risk factors.

The risk of SSRI-induced hyponatremia is magnified in advanced age and by the concurrent use of thiazide diuretics, which independently cause sodium depletion.

Recognizing overlapping medication toxicities dictates the required surveillance.

Select the appropriate guideline-concordant monitoring strategy.

Measure a basic metabolic panel (specifically serum sodium)

2

4

weeks after initiation of the SSRI.

Timely laboratory evaluation detects asymptomatic hyponatremia, allowing for early intervention before clinical deterioration occurs.

Key Concept

Elderly patients initiating SSRI therapy, particularly those concurrently using thiazide diuretics, are at high risk for developing hyponatremia secondary to SIADH and require serum sodium monitoring within 2 to 4 weeks.

Estimated Time:1m 0s

Question 100Question →

A 78-year-old female patient is evaluated during a routine ambulatory appointment at a geriatrics clinic. Her daughter, who provides collateral history, expresses concern regarding the patient's escalating confusion and recent onset of urinary dribbling over the past month. The patient's medical history includes major depressive disorder, essential hypertension, type 2 diabetes mellitus, and painful diabetic peripheral neuropathy. Her daily medication regimen consists of metformin, amlodipine, sertraline, amitriptyline (initiated four weeks ago for neuropathy), and over-the-counter diphenhydramine (taken nightly for insomnia).

Vital signs show a heart rate of 92/min. Blood pressure is 138/82 mm Hg while supine and 112/68 mm Hg upon standing. Physical examination is notable for dry oral mucous membranes, delayed capillary refill, and a mildly distended, palpable mass in the suprapubic region. A bedside ultrasound of the bladder demonstrates a postvoid residual volume of 550 mL.

Which of the following is the most appropriate initial pharmacologic intervention?

Initiate oral oxybutynin therapy

Initiate oral donepezil therapy

Discontinue amlodipine

Discontinue amitriptyline and diphenhydramine

Discontinue sertraline

Show answer & explanation

Answer: Discontinue amitriptyline and diphenhydramine

Answer

Discontinue amitriptyline and diphenhydramine

The correct answer involves discontinuing both amitriptyline and diphenhydramine. This patient is exhibiting a classic anticholinergic toxidrome (manifesting as confusion, dry mucous membranes, and urinary retention leading to overflow incontinence) caused by the synergistic effects of a tricyclic antidepressant (amitriptyline) and a first-generation antihistamine (diphenhydramine). Elderly patients are particularly susceptible to the cumulative anticholinergic burden of multiple medications due to decreased hepatic and renal clearance, as well as age-related changes in the central nervous system. Additionally, her significant orthostatic hypotension is a direct result of the alpha-1 adrenergic receptor blockade characteristic of tricyclic antidepressants. The most appropriate initial intervention is deprescribing these offending agents to reverse the toxicity.

Step-by-Step Solution

Analyze the patient's clinical presentation.

The patient presents with confusion, overflow urinary incontinence (postvoid residual 550 mL), dry mucous membranes, and severe orthostatic hypotension.

Synthesizing the physical findings and history is necessary to identify the underlying toxidrome.

Correlate the symptoms with the patient's medication list.

Amitriptyline and diphenhydramine are identified as medications with strong anticholinergic properties; amitriptyline additionally exerts significant alpha-1 adrenergic blocking effects.

Identifying the offending agents causing the adverse drug events is critical in the elderly, who are highly susceptible to polypharmacy cascades.

Determine the most appropriate clinical action.

The best intervention is to immediately discontinue the anticholinergic medications.

Reversing the toxidrome by removing the offending agents is the primary treatment before considering any alternative diagnostic or therapeutic pathways.

Key Concept

Cumulative anticholinergic burden in the elderly can present with delirium, overflow urinary incontinence, and dry mucous membranes, necessitating the prompt discontinuation of offending agents.

Alternative Method

A formal medication reconciliation utilizing the Beers Criteria or calculating the patient's Anticholinergic Cognitive Burden (ACB) score can systematically highlight the urgent need to deprescribe high-risk medications like amitriptyline and diphenhydramine.

Estimated Time:1m 15s

PreviousPage 5 / 237Next

All practice questions

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept